Amicus Therapeutics Stock Filter Stocks by Fundamentals
FOLD Stock | USD 10.54 0.17 1.59% |
Amicus Therapeutics fundamentals help investors to digest information that contributes to Amicus Therapeutics' financial success or failures. It also enables traders to predict the movement of Amicus Stock. The fundamental analysis module provides a way to measure Amicus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amicus Therapeutics stock.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 10.49 | 9.96 |
Amicus | Price to Sales |
Amicus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Amicus Therapeutics from analyzing Amicus Therapeutics' financial statements. These drivers represent accounts that assess Amicus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Amicus Therapeutics' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 2.3B | 6.0B | 3.1B | 3.5B | 4.2B | 4.4B | |
Enterprise Value | 2.4B | 6.3B | 3.3B | 3.8B | 4.4B | 4.6B |
Amicus Fundamentals
Return On Equity | -1.07 | ||||
Return On Asset | -0.0612 | ||||
Profit Margin | (0.38) % | ||||
Operating Margin | (0.03) % | ||||
Current Valuation | 3.35 B | ||||
Shares Outstanding | 295.38 M | ||||
Shares Owned By Insiders | 0.75 % | ||||
Shares Owned By Institutions | 99.25 % | ||||
Number Of Shares Shorted | 32.49 M | ||||
Price To Earning | (9.18) X | ||||
Price To Book | 19.70 X | ||||
Price To Sales | 7.90 X | ||||
Revenue | 399.36 M | ||||
Gross Profit | 290.63 M | ||||
EBITDA | (65.62 M) | ||||
Net Income | (151.58 M) | ||||
Cash And Equivalents | 386.84 M | ||||
Cash Per Share | 1.38 X | ||||
Total Debt | 445.06 M | ||||
Debt To Equity | 2.60 % | ||||
Current Ratio | 3.02 X | ||||
Book Value Per Share | 0.55 X | ||||
Cash Flow From Operations | (69.09 M) | ||||
Short Ratio | 9.84 X | ||||
Earnings Per Share | (0.51) X | ||||
Price To Earnings To Growth | (0.18) X | ||||
Target Price | 18.75 | ||||
Number Of Employees | 517 | ||||
Beta | 0.76 | ||||
Market Capitalization | 3.16 B | ||||
Total Asset | 777.88 M | ||||
Retained Earnings | (2.68 B) | ||||
Working Capital | 315.37 M | ||||
Current Asset | 216.6 M | ||||
Current Liabilities | 73.62 M | ||||
Net Asset | 777.88 M |
About Amicus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amicus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Amicus Therapeutics Investors Sentiment
The influence of Amicus Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amicus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amicus Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amicus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amicus Therapeutics' short interest history, or implied volatility extrapolated from Amicus Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Amicus Therapeutics Piotroski F Score and Amicus Therapeutics Altman Z Score analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
CEOs Directory Screen CEOs from public companies around the world | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 1.353 | Quarterly Revenue Growth 0.306 | Return On Assets (0.06) | Return On Equity (1.07) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.